New Test Available: FOLR1 Immunohistochemistry
The Ventana FOLR1 (FOLR1-2.1) RxDx assay is an FDA approved companion diagnostic test to detect the expression of folate receptor 1 on patients’ formalin fixed, paraffin embedded specimens of epithelial ovarian, fallopian tube, or primary peritoneal cancers, for selection of patients who are eligible for treatment with the antibody-drug conjugate mirvetuximab soravtansine-gynx (ELAHERE), who are resistant to platinum-based therapy.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant
Specimen requirements: FFPE tissue unstained sections on coated slides (4µm)
Turnaround time: 5 working days from day of specimen received
|
 |
|